https://www.selleckchem.com/pr....oducts/adenosine-dis
1%, 6.1%, and 4.5%, respectively. Use of biologics did not show a moderating effect on mechanical ventilation (p = 0.68), ICU admission (p = 0.27), or mortality (p = 0.2. Our findings advocate for the continued biologic therapy in IBD patients during the COVID-19 pandemic. Nevertheless, the incidence, severity, and outcomes related to COVID-19 in IBD patients' needs to be reassessed as data continues to emerge. Our findings advocate for the continued biologic therapy in IBD patients during the COVID-19 pandemic
Aimer
Commentaire
Partagez
